Therapy Areas: Oncology
WuXi Biologics receives South Korean certification for commercial manufacturing of bispecific antibody therapeutics
23 April 2026 - WuXi Biologics (HK:2269), a China-based global Contract Research, Development, and Manufacturing Organisation (CRDMO), announced on Thursday that three of its manufacturing facilities ...
Labcorp launches FDA-approved companion diagnostic to identify ovarian cancer patients' KEYTRUDA eligibility
23 April 2026 - US laboratory services provider Labcorp (NYSE:LH) announced on Wednesday the nationwide availability of Agilent Technologies' PD-L1 IHC 22C3 pharmDx, the only companion diagnostic...
PureTech Health reports positive Phase 1b data for LYT-200 in MDS and AML
22 April 2026 - Biotherapeutics company PureTech Health plc reported on Wednesday that its founded entity Gallop Oncology reported positive topline Phase 1b data for LYT-200 in relapsed/refractory hig...
FDA extends review timeline for Sanofi's Sarclisa subcutaneous formulation in multiple myeloma
22 April 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Wednesday that the US Food and Drug Administration (FDA) has extended by up to three months the tar...
Inhibrx provides clinical update on ozekibart (INBRX-109) for colorectal cancer treatment
22 April 2026 - Clinical-stage biopharmaceutical company Inhibrx Biosciences Inc (Nasdaq:INBX) on Tuesday reported updated interim data from its Phase 1/2 study evaluating ozekibart (INBRX-109) in com...
Lytix reports phase II results showing durable responses in advanced melanoma
21 April 2026 - Clinical-stage biotech company Lytix Biopharma ASA (Euronext Growth Oslo:LYTIX) on Tuesday reported final Phase II results for ruxotemitide (LTX-315) in combination with pembrolizumab ...